Weight Considerations in Pharmacotherapy for Type 2 Diabetes

Overview

Journal J Obes

Publisher Wiley

Specialty Endocrinology

Date 2010 Oct 2

PMID 20885921

Citations 15

Authors

Vicky Cheng

Sangeeta R Kashyap

Affiliations

Soon will be listed here.

Abstract

Obesity has been increasing in prevalence worldwide and the majority of patients with type 2 diabetes are either overweight or obese. Diabetes management in this population has been difficult since a number of antidiabetes agents are associated with weight gain. The effects of various antidiabetes agents and antiobesity agents on glycemic control and body weight will be reviewed. Briefly, sulfonylureas, thiazolidinediones, and insulin are associated with weight gain, whereas metformin and amylin analogs are weight neutral or associated with modest weight loss. Dipeptidyl-peptidase-4 inhibitors are weight neutral, whereas glucagon-like peptide-1 analogs are associated with weight loss. The effect of orlistat and sibutramine in type 2 diabetes is also evaluated. The treatment of diabetes should not only focus on glycemic control as its sole intention, but it should factor in the effect of these various agents on weight, as well, since obesity aggravates insulin resistance, beta cell failure, and cardiovascular risk.

Citing Articles

Metformin: Activation of 5' AMP-activated protein kinase and its emerging potential beyond anti-hyperglycemic action.

Goel S, Singh R, Singh V, Singh H, Kumari P, Chopra H Front Genet. 2022; 13:1022739.

PMID: 36386794 PMC: 9659887. DOI: 10.3389/fgene.2022.1022739.

Tirzepatide-Friend or Foe in Diabetic Cancer Patients?.

Samuel S, Varghese E, Kubatka P, Busselberg D Biomolecules. 2022; 12(11).

PMID: 36358930 PMC: 9687454. DOI: 10.3390/biom12111580.

Molecular docking analysis and anti-hyperglycaemic activity of Synacinn™ in streptozotocin-induced rats.

Ab Rahman N, Abdul Majid F, Abd Wahid M, Ismail H, Mohamed Tap F, Zainudin A RSC Adv. 2022; 10(57):34581-34594.

PMID: 35514405 PMC: 9058594. DOI: 10.1039/d0ra04664g.

The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients.

Albaker W, Al Sheikh M, Albakr A, Alkhafaji D, Al Besher E, Al-Hariri M Int J Gen Med. 2021; 14:8643-8650.

PMID: 34849008 PMC: 8627262. DOI: 10.2147/IJGM.S336904.

Medicinal Plant Extracts Evaluated and for Antidiabetic Activities in Ethiopia: Bases for Future Clinical Trials and Related Investigations.

Yikna B, Yehualashet A Evid Based Complement Alternat Med. 2021; 2021:9108499.

PMID: 34527069 PMC: 8437627. DOI: 10.1155/2021/9108499.

References

Garber A, Henry R, Ratner R, Garcia-Hernandez P, Rodriguez-Pattzi H, Olvera-Alvarez I . Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2008; 373(9662):473-81. DOI: 10.1016/S0140-6736(08)61246-5. View

Nathan D, Buse J, Davidson M, Ferrannini E, Holman R, Sherwin R . Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008; 32(1):193-203. PMC: 2606813. DOI: 10.2337/dc08-9025. View

Riddle M, Pencek R, Charenkavanich S, Lutz K, Wilhelm K, Porter L . Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care. 2009; 32(9):1577-82. PMC: 2732154. DOI: 10.2337/dc09-0395. View

DeFronzo R . Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004; 88(4):787-835, ix. DOI: 10.1016/j.mcna.2004.04.013. View

Rosenstock J, Davies M, Home P, Larsen J, Koenen C, Schernthaner G . A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008; 51(3):408-16. PMC: 2235909. DOI: 10.1007/s00125-007-0911-x. View

Knowler W, Barrett-Connor E, Fowler S, Hamman R, Lachin J, Walker E . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6):393-403. PMC: 1370926. DOI: 10.1056/NEJMoa012512. View

Goldstein B, Feinglos M, Lunceford J, Johnson J, Williams-Herman D . Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007; 30(8):1979-87. DOI: 10.2337/dc07-0627. View

Aronne L, Halseth A, Burns C, Miller S, Shen L . Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity (Silver Spring). 2010; 18(9):1739-46. DOI: 10.1038/oby.2009.478. View

DeFronzo R, Triplitt C, Qu Y, Lewis M, Maggs D, Glass L . Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care. 2010; 33(5):951-7. PMC: 2858197. DOI: 10.2337/dc09-1521. View

10.

. Prevalence of overweight and obesity among adults with diagnosed diabetes--United States, 1988-1994 and 1999-2002. MMWR Morb Mortal Wkly Rep. 2004; 53(45):1066-8. View

11.

Garber A, Donovan Jr D, Dandona P, Bruce S, Park J . Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab. 2003; 88(8):3598-604. DOI: 10.1210/jc.2002-021225. View

12.

Miles J, Leiter L, Hollander P, Wadden T, Anderson J, Doyle M . Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002; 25(7):1123-8. DOI: 10.2337/diacare.25.7.1123. View

13.

Smith S, Aronne L, Burns C, Kesty N, Halseth A, Weyer C . Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008; 31(9):1816-23. PMC: 2518351. DOI: 10.2337/dc08-0029. View

14.

James W, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A . Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010; 363(10):905-17. DOI: 10.1056/NEJMoa1003114. View

15.

Xiang A, Peters R, Kjos S, Marroquin A, Goico J, Ochoa C . Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes. 2006; 55(2):517-22. PMC: 1389697. DOI: 10.2337/diabetes.55.02.06.db05-1066. View

16.

Ratner R, Maggs D, Nielsen L, Stonehouse A, Poon T, Zhang B . Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2006; 8(4):419-28. DOI: 10.1111/j.1463-1326.2006.00589.x. View

17.

Frye R, August P, Brooks M, Hardison R, Kelsey S, MacGregor J . A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009; 360(24):2503-15. PMC: 2863990. DOI: 10.1056/NEJMoa0805796. View

18.

Hollander P, Levy P, Fineman M, Maggs D, Shen L, Strobel S . Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003; 26(3):784-90. DOI: 10.2337/diacare.26.3.784. View

19.

Russell-Jones D, Vaag A, Schmitz O, Sethi B, Lalic N, Antic S . Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009; 52(10):2046-55. PMC: 2744824. DOI: 10.1007/s00125-009-1472-y. View

20.

Kahn S, Haffner S, Heise M, Herman W, Holman R, Jones N . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355(23):2427-43. DOI: 10.1056/NEJMoa066224. View